Page 701

(2) plasma acylcarnitines;

(3) urine organic acids;

(4) total and free carnitine;

(5) total plasma homocysteine;

(6) urine acyglycines;

(7) urine amino acids;

(8) urine succinylacetone. (c) The health care provider who ordered the screening test in 7 AAC 27.530 may choose to use a diagnostic laboratory other than the designated laboratory for a diagnostic test required under (a) of this section of the specimen. However, the department will not pay for costs incurred by use of a nondesignated laboratory for the testing. (d) If diagnostic confirmatory testing is done through a nondesignated laboratory, the health care provider shall report, in writing, the results of the diagnostic testing to the newborn bloodspot screening program in the department, not later than two days after the date of receipt of results of the diagnostic testing. (e) When a newborn child has an abnormal screening test result and a diagnostic report is not received by the department from the health care provider, the department will contact the child’s health care provider. (f) The department will provide the child’s health care provider with a consultation with an appropriate medical specialist for a newborn child undergoing diagnostic testing due to abnormal screening results. (Eff. 12/30/77, Register 64; am 2/3/88, Register 105; am 7/13/94, Register 131; am 7/16/2011, Register 199; am 7/1/2018, Register 226) Statutory Authority: Authority: AS 18.05.040 AS 18.15.200 Editor’s note: The address for the newborn bloodspot screening (NBS) program in the department is the Department of Health, division of public health, section of women’s, children’s, and family health, 3601 C Street, Suite 322, Anchorage, Alaska 99503.